EBS
Price
$5.66
Change
-$0.22 (-3.74%)
Updated
May 14, 04:59 PM (EDT)
Capitalization
120.07M
90 days until earnings call
HROW
Price
$25.12
Change
-$1.15 (-4.38%)
Updated
May 14, 04:59 PM (EDT)
Capitalization
467.85M
90 days until earnings call
Ad is loading...

EBS vs HROW

Header iconEBS vs HROW Comparison
Open Charts EBS vs HROWBanner chart's image
Emergent Biosolutions
Price$5.66
Change-$0.22 (-3.74%)
Volume$9.15K
Capitalization120.07M
Harrow
Price$25.12
Change-$1.15 (-4.38%)
Volume$9.47K
Capitalization467.85M
EBS vs HROW Comparison Chart
Loading...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EBS vs. HROW commentary
May 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a Hold and HROW is a Hold.

Ad is loading...
COMPARISON
Comparison
May 15, 2025
Stock price -- (EBS: $5.88 vs. HROW: $26.27)
Brand notoriety: EBS and HROW are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EBS: 82% vs. HROW: 87%
Market capitalization -- EBS: $120.07M vs. HROW: $467.85M
EBS [@Pharmaceuticals: Other] is valued at $120.07M. HROW’s [@Pharmaceuticals: Other] market capitalization is $467.85M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.69B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EBS’s FA Score shows that 1 FA rating(s) are green whileHROW’s FA Score has 1 green FA rating(s).

  • EBS’s FA Score: 1 green, 4 red.
  • HROW’s FA Score: 1 green, 4 red.
According to our system of comparison, HROW is a better buy in the long-term than EBS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EBS’s TA Score shows that 6 TA indicator(s) are bullish while HROW’s TA Score has 6 bullish TA indicator(s).

  • EBS’s TA Score: 6 bullish, 3 bearish.
  • HROW’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, both EBS and HROW are a good buy in the short-term.

Price Growth

EBS (@Pharmaceuticals: Other) experienced а +22.76% price change this week, while HROW (@Pharmaceuticals: Other) price change was +8.91% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.84%. For the same industry, the average monthly price growth was +8.88%, and the average quarterly price growth was +20.74%.

Reported Earning Dates

EBS is expected to report earnings on Aug 12, 2025.

HROW is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+1.84% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HROW($468M) has a higher market cap than EBS($120M). HROW has higher P/E ratio than EBS: HROW (39.53) vs EBS (17.73). HROW YTD gains are higher at: -21.699 vs. EBS (-38.494). HROW has higher annual earnings (EBITDA): 9.95M vs. EBS (-518.2M). EBS has more cash in the bank: 112M vs. HROW (82.8M). HROW has less debt than EBS: HROW (191M) vs EBS (860M). EBS has higher revenues than HROW: EBS (1.02B) vs HROW (130M).
EBSHROWEBS / HROW
Capitalization120M468M26%
EBITDA-518.2M9.95M-5,206%
Gain YTD-38.494-21.699177%
P/E Ratio17.7339.5345%
Revenue1.02B130M787%
Total Cash112M82.8M135%
Total Debt860M191M450%
FUNDAMENTALS RATINGS
EBS vs HROW: Fundamental Ratings
EBS
HROW
OUTLOOK RATING
1..100
1513
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
77
Overvalued
PROFIT vs RISK RATING
1..100
10054
SMR RATING
1..100
9494
PRICE GROWTH RATING
1..100
5446
P/E GROWTH RATING
1..100
1011
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EBS's Valuation (57) in the Biotechnology industry is in the same range as HROW (77) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to HROW’s over the last 12 months.

HROW's Profit vs Risk Rating (54) in the Pharmaceuticals Other industry is somewhat better than the same rating for EBS (100) in the Biotechnology industry. This means that HROW’s stock grew somewhat faster than EBS’s over the last 12 months.

HROW's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as EBS (94) in the Biotechnology industry. This means that HROW’s stock grew similarly to EBS’s over the last 12 months.

HROW's Price Growth Rating (46) in the Pharmaceuticals Other industry is in the same range as EBS (54) in the Biotechnology industry. This means that HROW’s stock grew similarly to EBS’s over the last 12 months.

EBS's P/E Growth Rating (10) in the Biotechnology industry is in the same range as HROW (11) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to HROW’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EBSHROW
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 9 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Ad is loading...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PREKF17.090.23
+1.39%
Prairiesky Royalty Ltd.
GLXZ2.810.01
+0.43%
Galaxy Gaming, Inc.
NFEPX19.90N/A
N/A
Columbia Large Cap Growth Opp Inst
SAGYX135.85N/A
N/A
ClearBridge Growth I
CRRFY3.09-0.01
-0.32%
Carrefour S.A.

EBS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EBS has been loosely correlated with AMRX. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
+0.68%
AMRX - EBS
33%
Loosely correlated
-1.32%
HROW - EBS
31%
Poorly correlated
-1.46%
VTRS - EBS
29%
Poorly correlated
-1.90%
ZOMDF - EBS
29%
Poorly correlated
+13.73%
PAHC - EBS
27%
Poorly correlated
+0.41%
More

HROW and

Correlation & Price change

A.I.dvisor indicates that over the last year, HROW has been loosely correlated with AMRX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HROW
1D Price
Change %
HROW100%
-1.46%
AMRX - HROW
44%
Loosely correlated
-1.32%
EBS - HROW
31%
Poorly correlated
+0.68%
TLRY - HROW
30%
Poorly correlated
-1.94%
ETON - HROW
29%
Poorly correlated
-1.61%
ACB - HROW
28%
Poorly correlated
+1.98%
More